Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Assets: 2020-2025

Historic Assets for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $205.0 million.

  • Foghorn Therapeutics' Assets fell 33.53% to $205.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.0 million, marking a year-over-year decrease of 33.53%. This contributed to the annual value of $284.0 million for FY2024, which is 0.68% down from last year.
  • Foghorn Therapeutics' Assets amounted to $205.0 million in Q3 2025, which was down 9.40% from $226.2 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Assets high stood at $519.8 million for Q4 2021, and its period low was $186.1 million during Q3 2021.
  • Over the past 3 years, Foghorn Therapeutics' median Assets value was $285.9 million (recorded in 2023), while the average stood at $288.9 million.
  • Per our database at Business Quant, Foghorn Therapeutics' Assets soared by 133.21% in 2022 and then tumbled by 33.53% in 2025.
  • Foghorn Therapeutics' Assets (Quarterly) stood at $519.8 million in 2021, then fell by 22.10% to $404.9 million in 2022, then dropped by 29.38% to $285.9 million in 2023, then decreased by 0.68% to $284.0 million in 2024, then crashed by 33.53% to $205.0 million in 2025.
  • Its last three reported values are $205.0 million in Q3 2025, $226.2 million for Q2 2025, and $258.7 million during Q1 2025.